Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2019 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional...
November 05, 2019 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and nine months ended September 30, 2019. Recent...
August 06, 2019 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates

SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and six months ended June 30, 2019, and provided updates on...
June 24, 2019 16:06 ET | Source: Conatus Pharmaceuticals Inc.

Conatus to Explore Strategic Alternatives and Implement Restructuring Plan

SAN DIEGO, June 24, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that the company has engaged Oppenheimer & Co., Inc., as its financial advisor to assist...
June 24, 2019 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis

SAN DIEGO, June 24, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that top-line results from the company’s ENCORE-LF clinical trial of emricasan did not meet...
May 02, 2019 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports First Quarter 2019 Financial Results and Program Updates

SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2019, and provided updates on its...
April 30, 2019 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced a new publication1 in Hepatology Communications detailing results following seven-day...
April 15, 2019 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019,...
April 02, 2019 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

SAN DIEGO, April 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted an invitation to participate in the H.C. Wainwright Global Life Sciences Conference (April 7-9...
March 21, 2019 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis

SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with...